Zobrazeno 81 - 90
of 805
pro vyhledávání: '"Won Seog, Kim"'
Autor:
Do Young Kim, Yu Ri Kim, Cheolwon Suh, Dok Hyun Yoon, Deok-Hwan Yang, Yong Park, Hyeon Seok Eom, Jeong-Ok Lee, Jae-Yong Kwak, Hye Jin Kang, Shin Young Hyun, Jae-Cheol Jo, Myung Hee Chang, Kwai Han Yoo, Sung-Nam Lim, Ho-Jin Shin, Won Seog Kim, In-Ho Kim, Min Kyung Kim, Hyo Jung Kim
Publikováno v:
American Journal of Gastroenterology (Lippincott Williams & Wilkins); Aug2023, Issue 8, p1373-1380, 8p
Publikováno v:
Journal of Hematology & Oncology, Vol 9, Iss 1, Pp 1-4 (2016)
Abstract Aggressive nature killer cell leukemia (ANKL) is a mature NK-T cell lymphoma with worse prognosis, but optimal treatment is unclear. Therefore, we analyzed the efficacy of l-asparaginase-based regimens for ANKL patients. Twenty-one patients
Externí odkaz:
https://doaj.org/article/5e1c59438a064b0b9b504e878223190e
Publikováno v:
Hematological Oncology. 39:664-673
Peripheral T-cell lymphomas (PTCLs) are known to have an aggressive clinical course and grave prognosis. Several recommended first-line treatment regimens are available, but identification of the superior treatment remain elusive. We conducted a syst
Autor:
KeumYoung Ahn, Mariana Vasilica, Christian Buske, Rajnish Nagarkar, Edvard Zhavrid, Aliaksandr Prokharau, Sung-Hyun Kim, Juan-Manuel Sancho, Michinori Ogura, Won Seog Kim, Wojciech Jurczak, Jose Angel Hernandez-Rivas, Jin Seok Kim, Sang Joon Lee, Larry W. Kwak
Publikováno v:
Blood Adv
Rituximab biosimilars are a cornerstone of treatment of advanced-stage follicular lymphoma (FL). This double-blind, parallel-group, phase 3 trial randomized (1:1) adults (≥18 years) with stage III to IV indolent B-cell lymphoma, including grades 1
Publikováno v:
Cancer Management and Research
Chae Hong Lim,1 Sang Eun Yoon,2 Won Seog Kim,2 Kyung-Han Lee,3,4 Seok Jin Kim2,4 1Department of Nuclear Medicine, Soonchunhyang University College of Medicine, Seoul, Korea; 2Division of Hematology-Oncology, Department of Medicine, Samsung Medical Ce
Autor:
Dok Hyun Yoon, Youngil Koh, Miyoung Jung, Jeong-Eun Kwak, Eui-Cheol Shin, Yu Kyeong Hwang, Won Seog Kim
Publikováno v:
Transplantation and cellular therapy.
The prognosis of non-Hodgkin lymphoma (NHL) remains poor, with an unmet need for novel therapies. MG4101, an ex vivo-expanded allogeneic natural killer cell, can enhance rituximab antibody-dependent cytotoxicity in relapsed/refractory B-cell non-Hodg
Autor:
Ho-Young Yhim, Dok Hyun Yoon, Seok Jin Kim, Deok-Hwan Yang, Hyeon-Seok Eom, Kyoung Ha Kim, Yong Park, Jin Seok Kim, Hyo Jung Kim, Cheolwon Suh, Won Seog Kim, Jae-Yong Kwak
Publikováno v:
Cancers, Vol 12, Iss 8, p 2192 (2020)
There are limited data from prospective controlled trials regarding optimal treatment strategies in patients with primary breast diffuse large B-cell lymphoma (DLBCL). In this phase 2 study (NCT01448096), we examined the efficacy and safety of standa
Externí odkaz:
https://doaj.org/article/b5bc7c5189094769a3d7eb4562735341
Autor:
Monica Bellei, Francine M. Foss, Andrei R. Shustov, Steven M. Horwitz, Luigi Marcheselli, Won Seog Kim, Maria E. Cabrera, Ivan Dlouhy, Arnon Nagler, Ranjana H. Advani, Emanuela A. Pesce, Young-Hyeh Ko, Virginia Martinez, Silvia Montoto, Carlos Chiattone, Alison Moskowitz, Michele Spina, Irene Biasoli, Martina Manni, Massimo Federico
Publikováno v:
Haematologica, Vol 103, Iss 7 (2018)
This analysis explored factors influencing survival of patients with primary refractory and relapsed peripheral T-cell lymphomas enrolled in the prospective International T-cell Project. We analyzed data from 1020 patients with newly diagnosed diseas
Externí odkaz:
https://doaj.org/article/79f7373acd4c4f49a3efc28c780ef628
Autor:
Anas Younes, Gilles Salles, Giovanni Martinelli, Robert Gregory Bociek, Dolores Caballero Barrigon, Eva González Barca, Mehmet Turgut, John Gerecitano, Oliver Kong, Chaitali Babanrao Pisal, Ranjana Tavorath, Won Seog Kim
Publikováno v:
Haematologica, Vol 102, Iss 12 (2017)
Activation of the phosphatidylinositol 3-kinase/mechanistic target of rapamycin pathway plays a role in the pathogenesis of non-Hodgkin lymphoma. This multicenter, open-label phase 2 study evaluated buparlisib (BKM120), a pan-class I phosphatidylinos
Externí odkaz:
https://doaj.org/article/fbd61fce20ad4a2095ca685859c745c8
Publikováno v:
F1000Research, Vol 6 (2017)
Owing to the rarity of peripheral T-cell lymphoma (PTCL) and the heterogeneity of subtypes, there are no compelling data to guide the therapeutic approaches for such patients. Over the years, there have been remarkable advances in molecular subtyping
Externí odkaz:
https://doaj.org/article/609f508c93d546508de0c0058d3fdf51